Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Topoisomerase II alpha Antibodies:
anti-Rat (Rattus) Topoisomerase II alpha Antibodies:
anti-Human Topoisomerase II alpha Antibodies:
Go to our pre-filtered search.
Human Polyclonal Topoisomerase II alpha Primary Antibody for ICC, IF - ABIN4361369
Lindén, Segersten, Runeson, Wester, Busch, Pettersson, Lind, Malmström: Tumour expression of bladder cancer-associated urinary proteins. in BJU international 2013
Show all 2 Pubmed References
Human Monoclonal Topoisomerase II alpha Primary Antibody for IF, IHC (p) - ABIN563224
Poonperm, Takata, Hamano, Matsuda, Uchiyama, Hiraoka, Fukui: Chromosome Scaffold is a Double-Stranded Assembly of Scaffold Proteins. in Scientific reports 2015
Arabidopsis thaliana Polyclonal Topoisomerase II alpha Primary Antibody for IL, WB - ABIN334538
Xie, Lam: Abundance of nuclear DNA topoisomerase II is correlated with proliferation in Arabidopsis thaliana. in Nucleic acids research 1995
Show all 2 Pubmed References
Polyamide functionalisation at the N1-position offers a design strategy to improve drug-like properties. Dicationic HxIP* 3 increased topo IIalpha expression and chemosensitivity to topo II (show TOP2 Antibodies)-targeting agents.
We demonstrated that Nup98 (show NUP98 Antibodies)-TopIIbeta and Nup98 (show NUP98 Antibodies)-SETBP1 (show SETBP1 Antibodies) negatively regulate the XPO1 (show XPO1 Antibodies)-mediated protein export. Our results will contribute to the understanding of the molecular mechanism by which the Nup98 (show NUP98 Antibodies)-fusion proteins induce tumorigenesis.
TOP2 (show TOP2 Antibodies) and BAF (show BANF1 Antibodies) cooperate to recruit pluripotency factors, which explains some of the instructive roles of BAF (show BANF1 Antibodies) complexes.
Deletion or deficiency of PTEN (show PTEN Antibodies) leads to down regulation of TOP2A, dysfunction of the decatenation checkpoint and incomplete DNA decatenation in G2 and M phases.
Inhibition of DNA topoisomerase II (show TOP2 Antibodies) selectively reduces the threat of tumorigenicity
Cohesin removal is a prerequisite for the posterior topoisomerase IIalpha-mediated resolution of persisting catenations between segregating chromatids during anaphase II.
Data show that unfolded protein response (UPR)-induced changes in topoisomerase IIalpha (Topo IIalpha) protein levels are not responsible for resistance to etoposide, and that the PERK plays a Topo IIalpha-independent role in altered sensitivity to the drug.
TOP2beta (show TOP2B Antibodies) as a factor involved in regulating granulosa cell genomic integrity and follicle atresia.
Topoisomerase IIa not only contributes to stem-cell transcriptome regulation but also primes developmental genes for subsequent activation upon differentiation.
studies indicate that the ability of TOP2A to prevent DNA entanglement at mitosis requires BAF (show BANF1 Antibodies) complexes and suggest that this activity contributes to the role of BAF (show BANF1 Antibodies) subunits as tumour suppressors
Data show that comparing with Ki-67 (show MKI67 Antibodies) and TOP2A, RacGAP1 (show RACGAP1 Antibodies) allowed for a clearer prognostic statement.
These findings reveal a novel, p53 (show TP53 Antibodies)-independent activity of Mdm2 (show MDM2 Antibodies) and have important implications for the choice of chemotherapeutic agents in the treatment of Mdm2 (show MDM2 Antibodies)-overexpressing tumors. Herein is shown that tumor cells with MDM2 (show MDM2 Antibodies) amplification are selectively resistant to treatment with topoisomerase II (show TOP2 Antibodies) poisons but not other DNA damaging agents
The methodology is useful for a high-throughput analysis of drugs that poison Top2, allowing not just the discrimination of the Top2 isoform that is targeted but also to track its removal
TOP2A was identified in association with the progression and prognosis of pancreatic ductal adenocarcinoma probably by regulating cell cycle and p53 (show TP53 Antibodies) signaling pathway.
the relation between TOP2A levels and sensitivity for doxorubicin was examined, confirming reports that TOP2A mRNA levels were overexpressed in MPNST and showing that MPNST cell lines exhibited relatively high TOP2A protein levels and sensitivity to doxorubicin.
The decatenation checkpoint is regulated, not only by topo IIalpha, as previously reported, but also by topo IIbeta. The decatenation checkpoint is most efficient when both isoforms are present. Deletion of most of the C-terminus of topo IIalpha, while preserving the nuclear localization signal (NLS (show ALDH1A2 Antibodies)), enhances the decatenation checkpoint and sensitivity to topo II (show TOP2 Antibodies)-targeted drugs. Mutation of Y640 in topo IIalpha inhibi...
Tumors with higher topoisomerase IIalpha and/or mitosin (show CENPF Antibodies) expression have a higher risk of recurrence after initial treatment, and these patients may benefit from adjuvant treatment and closer radiological follow-up
Both the genome instability and cell death of MRE11 (show MRE11A Antibodies)-null and MRE11 (show MRE11A Antibodies)-mutated H129N cells are significantly reversed by overexpression of Tdp2 (show TDP2 Antibodies), an enzyme that eliminates covalent Top2 conjugates; thus, the essential role of Mre11 (show MRE11A Antibodies) nuclease (show DCLRE1C Antibodies) activity is likely to remove the DNA lesions.
we show that TopoIIalpha forms protein-protein interactions with beta-catentin and TCF4 (show TCF4 Antibodies) and interacts with Wnt (show WNT2 Antibodies) response elements (WREs) and promoters of direct target genes of TCF (show HNF4A Antibodies) transcription, including: MYC (show MYC Antibodies), vimentin (show VIM Antibodies), AXIN2 (show AXIN2 Antibodies) and LEF1 (show LEF1 Antibodies)
This study shows that both survivin (show BIRC5 Antibodies) and TIIalpha are independent prognostic predictors in human grade II/III astrocytomas stratified for IDH1 (show IDH1 Antibodies)-mutation status
This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromosome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia.
DNA topoisomerase II, alpha isozyme
, DNA Topoisomerase II alpha
, DNA topoisomerase 2-alpha
, topoisomerase (DNA) 2 alpha
, DNA gyrase
, DNA topoisomerase (ATP-hydrolyzing)
, DNA topoisomerase II, 170 kD
, DNA topoisomeraseII_alpha
, DNA topoisomerase 2-beta
, DNA topoisomerase II, beta isozyme